ScreenerHero

BCDA BioCardia, Inc.

NAS · US · Healthcare · Biotechnology · biocardia.com
1.090USD+2.83%Mkt Cap: 16.50M $P/E: —

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is Car…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap16.50M USD
Enterprise Value12.22M USD
Revenue (TTM)—
Gross Profit-4.19M USD
Net Income (TTM)-8.23M USD
Revenue/Share—
Last Price1.090 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.83
PEG—
EV/EBITDA-1.66
EV/Revenue—
P/S—
P/B5.89
EPS (TTM)-0.63
EPS (Forward)-0.58
52W Range
0.750032% of range1.800
52W High1.800 USD
52W Low0.7500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-919.33%
ROA-241.08%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.44M USD
CapEx (TTM)7.00K USD
FCF Margin—
FCF Yield-34.30%
Net Debt-3.82M USD
Net Debt/EBITDA0.52
Balance Sheet
Debt/Equity0.59
Current Ratio2.09
Quick Ratio2.02
Book Value/Sh0.18 USD
Cash/Share0.27 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 6, 2019
Splits
Last Split1:15
Split DateMay 30, 2024
Analyst Consensus
Rating—
Target (Mean)15.50 USD
Upside (mean)+1322.0%
Target Range6.000 USD – 25.00 USD
6.000+1322.0% to mean25.00
# Analysts2
Ownership
Shares Out.15.14M
Float12.26M
Insiders17.92%
Institutions14.79%
Short Interest
Short Ratio4.2d
Short % Float6.51%
Short % Out.5.70%
Shares Short863.66K
Short (prev mo.)1.03M
Technical
SMA 501.030 (+5.9%)
SMA 2001.107 (-1.5%)
Beta0.62
S&P 52W Chg16.45%
Avg Vol (30d)266.33K
Avg Vol (10d)120.21K
Technical Indicators
RSI (14)54.2
MACD0.0067
MACD Signal0.0117
MACD Hist.-0.0051
BB Upper1.197 USD
BB Middle1.083 USD
BB Lower0.9689 USD
BB Width21.07%
ATR (14)0.0695 USD
Vol Ratio (20d)0.54x